NCT07210515View on ClinicalTrials.gov

Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

March 31, 2026

Primary Completion Date

December 31, 2027

Study Completion Date

January 31, 2028

Conditions
Complex Regional Pain Syndrome Type I
Interventions
DRUG

Neridronate

neridronate 100 mg, given as a 2-hour infusion on Days 1, 4, 7, and 10.

DRUG

Placebo

placebo comparator

Sponsors
All Listed Sponsors
lead

Ambros Therapeutics, Inc.

INDUSTRY